Acumen Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Acumen Pharmaceuticals, Inc. (ABOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.14 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 647.54K shares, a 127.21% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.49M shares, a 37.47% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 79.76K shares, a 81.18% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 14.40K shares, a 93.33% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.19M shares, a 35.35% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.39M shares, a 65.56% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.04M shares, a 2.30% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.00M shares, a 29.59% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 647.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 3.14M shares 10-Q · filed 2026-08-12 | 3.22M shares derived: sum of 3 quarters · filed 2026-08-12 | 3.23M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 2.49M shares 10-Q · filed 2026-05-12 | 2.57M shares derived: sum of 2 quarters · filed 2026-05-12 | 2.58M shares derived: sum of 3 quarters · filed 2026-05-12 | 2.87M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 79.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 94.16K shares derived: sum of 2 quarters · filed 2026-03-26 | 379.16K shares derived: sum of 3 quarters · filed 2026-03-26 | 2.19M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 14.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 299.40K shares derived: sum of 2 quarters · filed 2025-11-12 | 2.11M shares 10-Q · filed 2025-11-12 | 2.53M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 285.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 2.09M shares 10-Q · filed 2025-08-12 | 2.52M shares derived: sum of 3 quarters · filed 2025-08-12 | 2.73M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 1.81M shares 10-Q · filed 2025-05-13 | 2.23M shares derived: sum of 2 quarters · filed 2025-05-13 | 2.45M shares derived: sum of 3 quarters · filed 2025-05-13 | 2.70M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 423.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 639.80K shares derived: sum of 2 quarters · filed 2025-03-27 | 894.10K shares derived: sum of 3 quarters · filed 2025-03-27 | 3.39M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 216.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 470.30K shares derived: sum of 2 quarters · filed 2024-11-12 | 2.96M shares 10-Q · filed 2024-11-12 | 3.09M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 254.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 2.75M shares 10-Q · filed 2024-08-13 | 2.87M shares derived: sum of 3 quarters · filed 2024-08-13 | 3.00M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 2.49M shares 10-Q · filed 2024-05-14 | 2.62M shares derived: sum of 2 quarters · filed 2024-05-14 | 2.74M shares derived: sum of 3 quarters · filed 2024-05-14 | 2.91M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 123.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 251.40K shares derived: sum of 2 quarters · filed 2024-03-26 | 417.00K shares derived: sum of 3 quarters · filed 2024-03-26 | 2.04M shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 127.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 293.20K shares derived: sum of 2 quarters · filed 2023-11-13 | 1.92M shares 10-Q · filed 2023-11-13 | 1.99M shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 165.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.79M shares 10-Q · filed 2023-08-08 | 1.86M shares derived: sum of 3 quarters · filed 2023-08-08 | 2.34M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 1.63M shares 10-Q · filed 2023-05-09 | 1.70M shares derived: sum of 2 quarters · filed 2023-05-09 | 2.17M shares derived: sum of 3 quarters · filed 2023-05-09 | 2.52M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 67.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 543.50K shares derived: sum of 2 quarters · filed 2023-03-27 | 894.50K shares derived: sum of 3 quarters · filed 2023-03-27 | 2.00M shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 476.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 827.50K shares derived: sum of 2 quarters · filed 2022-11-14 | 1.93M shares 10-Q · filed 2022-11-14 | 2.11M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 351.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 1.46M shares 10-Q · filed 2022-08-15 | 1.63M shares derived: sum of 3 quarters · filed 2022-08-15 | |
| 2022-03-31 | 1.10M shares 10-Q · filed 2022-05-16 | 1.28M shares derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2021-12-31 | 176.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 2.84M shares 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 2.66M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |